Side effects




Several monoclonal antibodies, such as Bevacizumab and Cetuximab, can cause different kinds of side effects. These side effects can be categorized into common and serious side effects.

Some common side effects include:

Among the possible serious side effects are:

Comments

Post a Comment

Popular posts from this blog

26)Republic Day Parade 2019: Indias rich cultural diversity about display at Rajpath; 10 tips

India Republic Day -- On Indias 70th Republic Day time Saturday the annual ornement in the national capital presented the countrys rich ethnical heritage and traditions. The actual central theme of the tableaux displayed was Mahatma Gandhi as 2019 marks the season of his 150th beginning anniversary. The might in the Indian military was about full display and in specific womens power. Before the ornement celebrations kicked off having Prime Minister Narendra Modi paying homage to the martyrs by laying a bridal flowers wreath at Amar Jawan Jyoti. At Rajpath the main Minister received President Ram memory Nath Kovind and South Africas President Cyril Ramaphosa who was the Chief Guest with Indias Republic Day 2019 event. President Kovind hoisted the tricolour as the national anthem played and a 21-gun salute was fired by simply seven cannons of 2281 Field Regiment. Republic Day time Parade 2019 * Assam Rifles tableau: Participating in typically the Republic Day parade at last in histo...
Read more

Cost

Image
Mabs are more expensive to manufacture than small molecules due to the complex processes involved and the general size of the molecules, this is all in addition to the enormous research and development costs involved in bringing a new chemical entity to patients. They are priced to enable manufacturers to recoup the typically large investment costs, and where there are no price controls, such as the United States, prices can be higher if they provide great value. Seven University of Pittsburgh researchers concluded, "The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states," comparing them on a per patient basis, to those for cardiovascular or metabolic disorders, immunology, infectious diseases, allergy, and ophthalmology.
Read more